Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Keating

Showing results (171-180 of 188) with videos related to

Pageof 19
Sort By:
Journal of Crohn'S & Colitis|April 13, 2024
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical ProgrammeLaurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Journal of Crohn'S & Colitis|June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 TrialsSéverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.
Frontiers in Immunology|January 31, 2018
The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by LenalidomideHila Shaim, Zeev Estrov, David Harris, et al.
British Journal of Haematology|June 28, 2019
Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patientsBoyu Hu, Keyur P Patel, Hsiang-Chun Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up resultsHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood|January 24, 2018
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomideKoichi Takahashi, Boyu Hu, Feng Wang, et al.
Blood Advances|October 26, 2022
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLLNitin Jain, Jayastu Senapati, Beenu Thakral, et al.
Leukemia & Lymphoma|March 8, 2022
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemiaSarah Tettamanti, Maria Caterina Rotiroti, Greta Maria Paola Giordano Attianese, et al.
The New England Journal of Medicine|February 6, 2020
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsEnli Liu, David Marin, Pinaki Banerjee, et al.
Pageof 19

Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
Journal of Crohn'S & Colitis|April 13, 2024
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical ProgrammeLaurent Peyrin-Biroulet, Marla C Dubinsky, Bruce E Sands, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylateHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Journal of Crohn'S & Colitis|June 15, 2024
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 TrialsSéverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, et al.
Frontiers in Immunology|January 31, 2018
The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by LenalidomideHila Shaim, Zeev Estrov, David Harris, et al.
British Journal of Haematology|June 28, 2019
Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patientsBoyu Hu, Keyur P Patel, Hsiang-Chun Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up resultsHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Blood|January 24, 2018
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomideKoichi Takahashi, Boyu Hu, Feng Wang, et al.
Blood Advances|October 26, 2022
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLLNitin Jain, Jayastu Senapati, Beenu Thakral, et al.
Leukemia & Lymphoma|March 8, 2022
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemiaSarah Tettamanti, Maria Caterina Rotiroti, Greta Maria Paola Giordano Attianese, et al.
The New England Journal of Medicine|February 6, 2020
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsEnli Liu, David Marin, Pinaki Banerjee, et al.
Pageof 19